In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Pilgrim, one of India's fastest-growing beauty and personal care brands, has successfully raised ₹200 crore in a mix of ...

Woollen rugs that resemble the side profiles of human faces are among 11 new products featured on Dezeen Showroom.

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

The founder and CEO of IPO-bound fintech Klarna took to X to once again explain why his company ditched Salesforce’s flagship CRM product about a year ago in favor of its own homegrown AI system.

they’re also using the new multimodal image-searching features Google debuted for its Vertex AI Search for healthcare product. The FDA published considerations for generative AI devices in ...

Google Cloud today announced new generative AI (gen AI) capabilities in Vertex AI Search for healthcare, including a new feature called Visual Q&A that searches tables, charts, and diagrams, and the ...